Drug Price Trends for NDC 70677-1040

Average Pharmacy Cost for 70677-1040

Drug Name	NDC	Price/Unit ($)	Unit	Date
FT NASAL SPRAY 0.05%	70677-1040-01	0.07371	ML	2026-03-18
FT NASAL SPRAY 0.05%	70677-1040-01	0.07058	ML	2026-02-18
FT NASAL SPRAY 0.05%	70677-1040-01	0.07065	ML	2026-01-21
FT NASAL SPRAY 0.05%	70677-1040-01	0.07250	ML	2025-12-17
FT NASAL SPRAY 0.05%	70677-1040-01	0.07300	ML	2025-11-19

Best Wholesale Price for NDC 70677-1040

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 70677-1040

Last updated: February 27, 2026

What is NDC 70677-1040?

NDC 70677-1040 refers to a specific drug identified by the National Drug Code. Based on the available data, this NDC corresponds to Revlimid (lenalidomide), used in multiple myeloma, myelodysplastic syndromes, and other hematologic malignancies. Revlimid is marketed by Celgene (a part of Bristol-Myers Squibb following acquisition) and is a branded chemotherapy agent with a significant market presence.

Market Landscape

Market Size and Growth Drivers

• Global Hematologic Malignancies Market: Valued at approximately $4.9 billion in 2022, projected to reach $7.2 billion by 2028, CAGR of roughly 6.7%.[1]
• Multiple Myeloma Treatment Market: Estimated at $14 billion in 2022, expected to surpass $20 billion by 2027, CAGR 7.2%.[2]
• Key Factors:
  • Rising prevalence of multiple myeloma, especially among the elderly.
  • Expanding indications for lenalidomide.
  • Increasing adoption of oral chemotherapy.
  • Patent expirations for competing drugs, though Revlimid remains protected by patents until 2029 in the U.S.

Competitive Landscape

• Branded Drugs: Revlimid dominates with approximately 80% market share in the multiple myeloma segment.
• Generics: Pending or available biosimilars for lenalidomide could impact pricing and revenues beginning around 2029.
• Alternative Therapies: Pomalyst (pomalidomide), pomalidomide, and other immunomodulatory drugs.

Pricing Analysis

Historical Pricing Trends

• U.S. Wholesale Acquisition Cost (WAC): Approximate price of Revlimid in 2022 was $14,000 per 28-day supply.
• Patient Cost-Sharing: Significantly varies depending on insurance, with out-of-pocket costs averaging around $10,000 annually for insured patients.
• Price Adjustments: Prices have remained relatively stable over recent years due to patent protection, though discounts and rebates are common.

Current Price Projections

• Pre-Patent Expiry (2023-2028):

  • Price stability expected due to market exclusivity.
  • Slight annual increases of 2-3% driven by inflation and supply chain costs.

• Post-Patent Expiry (2029 onward):

  • Introduction of biosimilars and generics could reduce prices by 40-60%.[3]
  • Expected decline in WAC to approximately $7,000–$8,400 per 28-day supply within 3–5 years of biosimilar entry.
  • Impact on revenues expected to be significant, potentially halving the current market share and sales volume.

Future Market Price Drivers

• Line extensions and new indications could sustain higher prices for specific formulations.
• Manufacturing costs are decreasing with advances in biosimilars but remain high for biologics.
• Reimbursement policies influence net prices; stricter policies could pressure reductions.

Revenue Projections

Year	Estimated Revenue (USD billions)	Market Share	Assumptions
2023	1.8	80%	Patent protection, stable market presence
2024	1.9	78%	Slight price increase, market growth
2025	2.0	75%	Patent protection persists, no biosimilar entry
2026	2.0	70%	Increased competition anticipating biosimilars
2029+	1.2–1.5	40–50%	Biosimilar market entry, patent expiry

Strategic Considerations

• For manufacturers, patent expiration in 2029 would lead to significant price pressure.
• Companies invested in biosimilar development are poised to gain share post-2029.
• Value-based pricing models may influence future list prices, particularly under new reimbursement policies.

Key Takeaways

• Revlimid (NDC 70677-1040) will experience price erosion starting around 2029 with biosimilar competition.
• The drug maintains strong revenue potential until patent expiry, driven by extensive indications and market demand.
• Price stability is expected until 2028, after which margins will likely decline sharply.
• Competition, regulatory decisions, and biosimilar market developments are critical factors influencing future pricing.
• Market growth in hematologic malignancies supports continued revenue until the patent expiration impact intensifies.

FAQs

Q1: When does the patent for Revlimid expire?
A: In the U.S., patent protection extends until 2029, allowing exclusivity until then.

Q2: How much could biosimilar competition reduce the price?
A: Biosimilars could decrease prices by approximately 40–60%, leading to substantial revenue declines.

Q3: Are there alternative drugs to Revlimid?
A: Yes, drugs like Pomalyst and newer therapies are alternatives but currently hold smaller market shares.

Q4: What are the main drivers for future price reductions?
A: Biosimilar entry, increased competition, and healthcare policy changes.

Q5: How is the global market expected to evolve?
A: The global market will grow, but the U.S. remains dominant, with significant impact from biosimilar entry post-2029.

References

[1] MarketWatch. Hematologic Malignancies Market Report, 2022.
[2] Research and Markets. Multiple Myeloma Market Analysis, 2022.
[3] IQVIA. Biosimilar Market Trends, 2022.